FDA Halts National Priority Voucher Drug Review Program

The signal here is procedural uncertainty rather than a clean policy reversal: FDA leadership says the voucher pathway is dead while HHS says the pilot continues and applications remain open, leaving sponsors with no clear read on whether submissions have any value. That contradiction matters most for developers who timed filings around the program. Whether the two agencies reconcile their positions, and whether the June hearing feedback translates into a revised framework, is the open question worth watching.